Business
Scholar Rock Appoints Tony Kingsley as President and CEO
- Nagesh Mahanthappa, Ph.D., MBA, company’s founding chief executive, passes the baton after leading company since 2012 - Tony Kingsley, a proven leader with
About this update from Scholar Rock Holding Corporation
[{"type":"text","content":"\n- Nagesh Mahanthappa, Ph.D., MBA, company’s founding chief executive, passes the baton after leading company since 2012\n\n\n- Tony Kingsley, a proven leader with a successful track record of advancing companies, to lead through next phase of clinical development growth and commercial preparedness \n\n\n- Company on-track for clinical data readouts in 2020 and 2021 from SRK-015 Phase 2 clinical trial in Spinal Muscular Atrophy and SRK-181 Phase 1 clinical trial in cancer immunotherapy\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nScholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tony Kingsley as president and chief executive officer, effective August 1, 2020. Mr. Kingsley, who was appointed to Scholar Rock’s Board of Directors in May, replaces Nagesh K. Mahanthappa, Ph.D., MBA, who has chosen to step down after serving in this role since 2012. Dr. Mahanthappa will also be stepping down from the Board of Directors on August 1, 2020, after which he will serve as a scientific advisor to the company.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005261/en/Tony Kingsley (Photo: Business Wire)\n\n“Scholar Rock is at an exciting inflection point, with great scientific strength, two product candidates in clinical development and multiple milestones in 2020 and 2021,” said Mr. Kingsley. “I look forward to working with our extraordinary team to continue advancing our highly innovative research and platform capabilities, as well as lead the company through its next phase of growth, bringing desperately needed therapies to patients who often have limited treatment options.”\n\n\nMr. Kingsley is an experienced CEO and a leader with a track record of driving growth, strategy and all facets of corporate operations. He was most recently president and chief executive officer of Taris Bio, prior to its acquisition by Janssen Pharmaceuticals at the end of 2019. Prior to Taris, he served as president and chief operating officer of The Medicines Company, and from 2010 to 2015, Mr. Kingsley led global commercial operations at Biogen, Inc. as executive vice president. Prior to Biogen, he held leadership roles in the medical devic...